Privi Speciality Chemicals Ltd
Incorporated in 1985, Privi Speciality Chemicals Ltd (Formerly known as Privi Speciality Ltd.) is primarily engaged in the manufacturing, supply and exports of aroma and fragrance chemicals used in soaps, detergents, shampoos, and other fine fragrances. [1]
- Market Cap ₹ 12,792 Cr.
- Current Price ₹ 3,275
- High / Low ₹ 3,785 / 2,569
- Stock P/E 32.6
- Book Value ₹ 410
- Dividend Yield 0.31 %
- ROCE 26.6 %
- ROE 28.2 %
- Face Value ₹ 10.0
Pros
- Company has delivered good profit growth of 29.0% CAGR over last 5 years
- Company's median sales growth is 16.2% of last 10 years
Cons
- Stock is trading at 7.99 times its book value
- Promoter holding has decreased over last 3 years: -13.4%
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 151 | 152 | 185 | 236 | 250 | 1,295 | 1,255 | 1,391 | 1,578 | 1,712 | 2,038 | 2,456 | 2,556 | |
| Sales growth | -1% | +1% | +22% | +27% | +6% | +418% | -3% | +11% | +13% | +9% | +19% | +20% | +11% |
| 126 | 128 | 162 | 202 | 213 | 1,080 | 1,048 | 1,195 | 1,394 | 1,383 | 1,590 | 1,795 | 1,877 | |
| Operating Profit | 25 | 23 | 24 | 34 | 36 | 215 | 207 | 197 | 184 | 329 | 448 | 661 | 679 |
| OPM % | 17% | 15% | 13% | 14% | 15% | 17% | 16% | 14% | 12% | 19% | 22% | 27% | 27% |
| 1 | 0 | 0 | 3 | 4 | 66 | 43 | 38 | 21 | 21 | 18 | 17 | 35 | |
| Interest | 3 | 4 | 5 | 6 | 6 | 36 | 23 | 25 | 68 | 97 | 85 | 68 | 56 |
| Depreciation | 2 | 3 | 4 | 5 | 5 | 55 | 69 | 73 | 105 | 122 | 127 | 130 | 133 |
| Profit before tax | 21 | 17 | 15 | 26 | 29 | 189 | 158 | 137 | 31 | 132 | 254 | 479 | 525 |
| Tax % | 33% | 36% | 39% | 25% | 26% | 24% | 26% | 26% | 28% | 26% | 25% | 25% | |
| 14 | 11 | 9 | 19 | 22 | 144 | 117 | 102 | 22 | 98 | 189 | 357 | 392 | |
| EPS in Rs | 9.92 | 7.68 | 2.41 | 5.16 | 5.50 | 36.83 | 29.93 | 26.00 | 5.75 | 25.03 | 48.41 | 91.42 | 100.25 |
| Dividend Payout % | 25% | 33% | 42% | 29% | 45% | 4% | 7% | 8% | 0% | 8% | 10% | 11% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 32% |
| 5 Years: | 14% |
| 3 Years: | 16% |
| TTM: | 11% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 42% |
| 5 Years: | 29% |
| 3 Years: | 150% |
| TTM: | 40% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 23% |
| 5 Years: | 14% |
| 3 Years: | 37% |
| 1 Year: | 10% |
| Return on Equity | |
|---|---|
| 10 Years: | 17% |
| 5 Years: | 16% |
| 3 Years: | 20% |
| Last Year: | 28% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 14 | 14 | 38 | 38 | 39 | 39 | 39 | 39 | 39 | 39 | 39 | 39 | 39 |
| Reserves | 43 | 49 | 33 | 48 | 64 | 564 | 675 | 768 | 783 | 881 | 1,062 | 1,399 | 1,563 |
| 29 | 34 | 60 | 67 | 57 | 493 | 517 | 897 | 1,043 | 900 | 856 | 729 | 705 | |
| 20 | 18 | 23 | 24 | 28 | 269 | 291 | 424 | 478 | 368 | 516 | 717 | 711 | |
| Total Liabilities | 105 | 114 | 154 | 176 | 188 | 1,364 | 1,522 | 2,128 | 2,343 | 2,189 | 2,473 | 2,883 | 3,018 |
| 62 | 73 | 94 | 102 | 115 | 564 | 565 | 666 | 982 | 999 | 979 | 1,005 | 970 | |
| CWIP | 8 | 5 | 3 | 3 | 1 | 30 | 174 | 370 | 93 | 27 | 70 | 234 | 362 |
| Investments | 0 | 0 | 0 | 0 | 0 | 43 | 43 | 51 | 51 | 62 | 62 | 112 | 117 |
| 36 | 36 | 57 | 72 | 72 | 727 | 740 | 1,042 | 1,217 | 1,101 | 1,363 | 1,532 | 1,569 | |
| Total Assets | 105 | 114 | 154 | 176 | 188 | 1,364 | 1,522 | 2,128 | 2,343 | 2,189 | 2,473 | 2,883 | 3,018 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 32 | 16 | 4 | 15 | 34 | 216 | 152 | 15 | 55 | 362 | 304 | 559 | |
| -25 | -13 | -20 | -13 | -14 | -174 | -242 | -324 | -141 | -118 | -144 | -354 | |
| -7 | -3 | 17 | -3 | -21 | 29 | 19 | 324 | 70 | -239 | -135 | -212 | |
| Net Cash Flow | 0 | -0 | 0 | -0 | 0 | 72 | -71 | 15 | -16 | 6 | 25 | -7 |
| Free Cash Flow | 7 | 3 | 4 | 15 | 17 | 46 | -90 | -301 | -87 | 259 | 156 | 256 |
| CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit | 150% | 81% | 36% | 61% | 107% | 131% | 92% | 24% | 37% | 118% | 84% | 102% |
Ratios
Standalone / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 42 | 41 | 50 | 49 | 47 | 61 | 69 | 75 | 73 | 77 | 72 | 87 |
| Inventory Days | 50 | 49 | 69 | 71 | 76 | 145 | 158 | 254 | 293 | 229 | 246 | 222 |
| Days Payable | 28 | 10 | 18 | 17 | 22 | 74 | 91 | 140 | 117 | 108 | 138 | 167 |
| Cash Conversion Cycle | 65 | 80 | 101 | 103 | 101 | 132 | 136 | 189 | 249 | 198 | 180 | 142 |
| Working Capital Days | 18 | 6 | 3 | 9 | 8 | 32 | 63 | 18 | 15 | 41 | 37 | 57 |
| ROCE % | 29% | 23% | 17% | 22% | 23% | 30% | 14% | 11% | 6% | 12% | 18% | 27% |
Insights
In beta| Jul 2016 | Jul 2017 | Sep 2020 | Jan 2022 | Mar 2023 | Jul 2024 | May 2026 | |
|---|---|---|---|---|---|---|---|
| Sales Volume MT |
|
||||||
| Number of Countries Exported To count |
|||||||
| Number of Manufacturing Facilities count |
|||||||
| CST Processing Capacity MTPA |
|||||||
| Number of Products count |
|||||||
| Total Production Capacity MTPA |
|||||||
| R&D Team Strength count |
|||||||
Extracted by Screener AI
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
- Announcement under Reg 30 - Transcript of Q2 Earnings Call held on October 30, 2026.
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
- Audio recording of investor call on Q2/H1 FY2026-27 unaudited results, held October 30, 2026.
-
Announcement under Regulation 30 (LODR)-Investor Presentation
- Investor Presentation - Financial & Operational Review for Quarter and half year ended September 30,2026.
-
Outcome Of Board Meeting - 29.10.2026
- Board approved Q2/H1 FY27 results, Rs 5 interim dividend, Rs 2.97 crore investment, and amalgamation scheme approval.
- Outcome Of Board Meeting - Approving Record Date For The Purpose Of Interim Dividend
Annual reports
-
Annual Report 2026
from bse
-
Annual Report 2025
from bse
-
Annual Report 2024
from bse
-
Annual Report 2023
from bse
-
Annual Report 2022
from bse
-
Annual Report 2021
from bse
-
Annual Report 2020
from bse
-
Annual Report 2019
from bse
-
Annual Report 2018
from bse
-
Annual Report 2017
from bse
-
Annual Report 2016
from bse
-
Annual Report 2015
from bse
-
Annual Report 2014
from bse
-
Annual Report 2013
from bse
-
Annual Report 2012
from bse
Concalls
-
Nov 2026Transcript PPT REC
-
Aug 2026Transcript PPT REC
-
May 2026Transcript PPT REC
-
Feb 2026Transcript PPT REC
-
Nov 2025Transcript PPT REC
-
Aug 2025Transcript PPT REC
-
May 2025Transcript PPT REC
-
Feb 2025Transcript PPT REC
-
Oct 2024Transcript PPT
-
Aug 2024Transcript PPT
-
Jul 2024Transcript PPT
-
May 2024Transcript PPT
-
Feb 2024Transcript REC
-
Nov 2023Transcript REC
-
Aug 2023REC
-
Jun 2023REC
-
Feb 2023PPT
-
May 2022Transcript
-
Jan 2022Transcript PPT
-
Jul 2017PPT
-
Jul 2016PPT
-
Nov 2011Transcript
Business Profile[1]
Privi Speciality Chemicals Limited, formerly Fairchem Speciality Limited, is India’s largest manufacturer and exporter of aroma chemicals, holding a >20% global market share in ten products. The company specializes in manufacturing, supplying, and exporting bulk aroma and fragrance chemicals.[2]